ArticleJHEP reports : innovation in hepatology2026
Platelet hyperactivation drives oxidized mitochondrial DNA-induced neutrophil extracellular traps formation in biliary atresia.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsBiliary atresia (BA) is a progressive neonatal cholangiopathy characterized by unresolved inflammation and neutrophil extracellular traps (NET) formation. Although neutrophils contribute to bile duct injury, the upstream mechanisms driving their activation remain poorly defined. This study investigated whether platelet (PLT) hyperactivation promotes NET-mediated inflammation in BA and evaluated the therapeutic potential of targeting S100A8/A9.
methodsThe role of PLT hyperactivation in neutrophil-mediated inflammation in BA was evaluated through retrospective clinical review, single-cell RNA sequencing, and cell coculture experiments. The therapeutic potential of paquinimod, a small-molecule inhibitor that blocks S100A8/A9 binding to Toll-like receptor 4 on PLT and thereby suppresses PLT activation, was evaluated in a murine model of BA.
resultsElevated PLT counts were observed in 54.2% (236/435) of patients with BA, and PLT hyperactivation (CD62p
conclusionsPLT hyperactivation drives ox-mtDNA-dependent NET formation and amplifies inflammatory signaling in BA. Pharmacological inhibition of S100A8/A9 with paquinimod attenuates disease progression in mice. IMPACT AND IMPLICATIONS: Biliary atresia is a serious neonatal liver disease featuring bile duct inflammation and obstruction. Here, hyperactivated PLTs in biliary atresia patients released ox-mtDNA, triggering NET formation and exacerbating liver injury. Blocking the key inflammatory mediator S100A8/A9 with paquinimod reduced PLT activation and liver inflammation and improved survival in mice. These findings reveal a vicious immune cycle between PLTs and neutrophils and highlight novel treatment options for attenuating disease progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.